Skip to main content
. 2017 Oct 24;12(6):815–826. doi: 10.1007/s11523-017-0528-z

Table 1.

Ceritinib and dasatinib IC50-values for ARMS and ERMS cell lines

Treatment Cell line (IC50 ± SD)
ARMS ERMS
Rh30 Rh41 RD Rh18
Ceritinib (μM) 0.50 ± 0.19 0.30 ± 0.09 0.87 ± 0.02 1.0 ± 0.71
Dasatinib (μM) 0.64 ± 0.04 6.44 ± 0.43 6.88 ± 2.87 0.31 ± 0.18

ARMS alveolar rhabdomyosarcoma, ERMS embryonal rhabdomyosarcoma, IC50 concentration at which 50% of the cell viability is affected, SD standard deviation